Gilead expands voluntary licensing collaborations for once-yearly lenacapavir

WHAT CHINWAGY KNOWS

The collaboration
is confirmed.

Gilead expanded six royalty-free voluntary licensing agreements covering investigational once-yearly lenacapavir for HIV prevention in 120 high-incidence countries, supporting manufacturing readiness, technology transfer and future supply planning.

Current status

Official collaboration

Known availability

The published source describes the collaboration; timing details remain under review.

Place

Foster City, United States

Source checked

September 18, 2026